Prognostic effect of cachexia in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.

ABSTRACT:

Background

The presence of cachexia in cancer patients negatively affects the quality of life and survival. However, the impact of cachexia on immunotherapy, such as PD-1/L1 inhibitors, is not fully understood. Therefore, we examined whether cancer cachexia affects the prognosis of patients with non-small cell lung cancer (NSCLC) treated with PD-1/PD-L1 inhibitors.

Methods

We retrospectively screened patients with pathologically confirmed advanced or recurrent NSCLC who were treated with PD-1/PD-L1 monotherapy at Kurume University Hospital. We defined cancer cachexia as weight loss of at least 5% during the past 6 months or any degree of weight loss more than 2% and BMI <20.

Results

Among 182 patients, 74 had cancer cachexia. The presence of cachexia was significantly

SUBMITTER: Matsuo N 

PROVIDER: S-EPMC10212657 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature